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Chromogranin A in uremia: Progressive retention of immunoreactive
fragments. Chromogranin A is a soluble protein that is stored and
released with catecholamines from their secretory vesicles. Its mea-
surement is a probe of exocytotic sympathoadrenal activity, and in
plasma it may also be a useful tool in the diagnosis of peptide producing
endocrine neoplasms. Because we have found that chromogranin A is
elevated in secondary (uremic) hyperparathyroidism, we systematically
investigated the influence of renal dysfunction and its attendant hyper-
parathyroidism on chromogranin A in several subject groups: normal
controls (serum creatinine 1.2 mg/dl), nonazotemic renal transplant
recipients, nonazotemic subjects with glomerular disease (serum creat-
mine between 1.2 and 2 mg/dl), mid-range renal disease subjects (serum
creatinine between 2 and 7.5 mgldl), and end-stage renal disease
subjects (serum creatinine >7.5 mg/dl). Plasma chromogranin A rose
with deterioration of renal function, and the rise was independent of
etiologic diagnosis, blood pressure, or indices of sympathoadrenal
activity or hyperparathyroidism. Size fractionation of uremic plasma by
gel filtration, and immunoextraction by region-specific anti-chromo-
granin A (anti-N-terminal, anti-C-terminal, and anti-mid-molecule) an-
tibodies 'iggested that chromogranin A immunoreactivity circulates in
uremia as lower molecular weight fragments of the parent chromogranin
A molecule, with mid-molecule fragments the major constituent. This
immunoreactivity is only minimally removed by peritoneal dialysis and
is not at all hemodialyzable. The uremia-dose-dependent accumulation
of chromogranin A immunoreactive fragments in renal failure suggests
that the kidney is a major site of disposition or removal of the
immunoreactivity. Furthermore, lack of detectable chromogranin A
immunoreactivity in normal subjects' urine suggests that the immuno-
reactivity is destroyed as it is removed by the kidney. We conclude that
plasma chromogranin A increases in proportion to degree of renal
insufficiency and that renal function must therefore be controlled when
using plasma chromogranin A in the investigation of amine or peptide
hormone storage and release.
Chromogranin A [1, 2] is an acidic, monomeric protein which
is stored and released with catecholamines by exocytosis from
secretory vesicles in the adrenal medulla [3, 4]. We have found
elevated plasma chromogranin A in subjects with peptide
hormone producing neoplasia, such as pheochromocytoma,
parathyroid adenoma or hyperplasia, thyroidal C cell disorders,
carcinoid tumor, oat cell lung carcinoma, and pancreatic islet-
cell tumor [5]. Indeed, measurement of circulating chromogra-
nm A concentration may be a valuable diagnostic tool for these
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endocrine tumors [5]. In the evaluation of hyperparathyroidism,
we also found elevated plasma chromogranin A concentration
in patients with secondary (uremic) hyperparathyroidism [5].
Since uremia per se may alter peptide hormone metabolism [6],
and since chromogranin A may be identical to parathyroid
secretory protein/secretory protein I [7], we wondered whether
the rise in chromogranin A in secondary hyperparathyroidism
was the result of renal dysfunction alone, or hyperparathyroid-
ism, or both.
In this study, we investigated the influence of renal dysfunc-
tion and the etiology of renal failure on plasma chromogranin A
concentration, the removal of chromogranin A by either hemo-
dialysis or peritoneal dialysis, and the correspondence of blood
pressure or indices of sympathoadrenal or parathyroid function
with plasma chromogranin A concentration. The results suggest
that plasma chromogranin A increases progressively in renal
failure, independently of etiologic diagnosis or parathyroid
status.
Methods
Human samples
Serum or plasma samples were obtained for the measurement
of chromogranin A, parathyroid hormone, creatinine and cate-
cholamines from 37 healthy controls (26 male and 11 female) as
well as subjects with various kinds and degrees of renal
dysfunction (N = 105, 73 male and 32 female): nonazotemic
renal transplant recipients (N = 5, 4 male and 1 female),
nonazotemic glomerulonephritis (N = 8, 6 male and 2 female),
mid-range renal disease (N = 30, 24 male and 6 female), and
end-stage renal disease (N 62, 39 male and 23 female). The
criterion for renal function group was the serum creatinine:
serum creatinine  1.2 mg/dl (range 0.5 to 1.2) for normal
controls, serum creatinine <2 mg/dl (range 1.3 to 1.9) for
nonazotemic renal transplant recipients, serum creatinine also
<2 mg/dl (range 0.7 to 1.8) for the nonazotemic glomerulone-
phritis group, serum creatinine between 2 and 7.5 mg/dl (range
2 to 7.3) for the mid-range renal disease group, and serum
creatinine >7.5 mg/dl (range 7.7 to 27) for the end-stage renal
disease group.
To evaluate whether the rise in plasma chromogranin A in
uremia is a result of augmented sympathoadrenal activity,
samples were obtained for the analysis of plasma chromogranin
A, creatinine, and catecholamines from three groups of pa-
tients: normal controls (N = 37), mid-range renal disease (N =
5), and hemodialyzed end-stage renal disease at the beginning of
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a hemodialysis treatment (N = 9). The end-stage renal disease
patients were further stratified into two subgroups: a high
chromogranin A group with plasma concentration >500 nglml,
and a lower chromogranin A group with plasma concentration
<500 ng/ml.
To determine if etiology of renal disease influences the
concentration of plasma chromogranin A, the 62 patients from
the end-stage renal disease group were subdivided into five
groups according to their etiologic clinical diagnosis: glomeru-
lonephritis (N = 28), diabetes mellitus (N = 14), polycystic
kidney disease (N = 7), tubulointerstitial nephritis (N = 6), and
hypertension (N = 7). Plasma chromogranin A concentration
was then compared among these five groups using a one-way
analysis of variance (ANOVA).
To determine whether plasma chromogranin A is removed by
either hemodialysis or peritoneal dialysis, nine end-stage renal
disease subjects were evaluated. In five subjects already on a
thrice weekly hemodialysis regimen, arterial blood was ob-
tained immediately before and after a four hour course of
hollow-fiber dialyzer hemodialysis; plasma chromogranin A and
total protein were measured. In addition, dialysate was also
obtained for analysis after countercurrent exposure to blood
across the hollow fiber membrane. Four subjects on continuous
ambulatory peritoneal dialysis (CAPD) used Travenol 1.5% to
2.5% dextrose dialysate (Baxter-Travenol, Chicago, Illinois,
USA), with an exchange volume of 2 liters. Dwell times were
four hours (N = 2), five hours (N = 1), or 72 hours (N = 1).
Venous blood and peritoneal dialysate were obtained at the end
of each dwell for the measurement of chromogranin A and total
protein concentration.
Plasma and urine samples were obtained from subjects with
proteinuria (N = 6) and normal controls (N = 6) for the
measurement of chromogranin A, creatinine and protein con-
centration. The criterion for proteinuria was 2+ urinary
protein by color reaction on Chemstrip 6L (Boehringer Mann-
heim Diagnostics, Indianapolis, Indiana, USA).
Venous catheterization
Venous samples from a secondary (uremic) hyperparathyroid
subject were obtained at different locations in the neck region
for the analysis of parathyroid hormone and chromogranin A.
Gel filtration
To ascertain the size distribution of plasma chromogranin A
immunoreactivity in renal failure, selected plasma samples (100
to 500 d) from end-stage renal disease patients were gel-filtered
at 2 ml per hour, collecting 0.5 ml fractions from a 55 by 0.9 cm
column of Ultrogel ACA-22 (LKB Produkter, Bromma, Swe-
den) that was equilibrated and eluted with 0.15 M sodium
chloride, 0,1% (wt/vol) ovalbumin, 0.1% (wt/vol) sodium azide,
and 0.01 M sodium phosphate (pH 7.4). The column had
previously been standardized for void volume (V0) by elution of
blue dextran, for total internal volume (V1) by elution of
potassium chloride and for the elution position of purified,
'251-labeled human chromogranin A. Each column run included
potassium chloride as an internal standard for V. The column
was chosen to provide optimal separation of 1251-labeled chro-
mogranin A from both V0 and Vt (8]. The distribution coefficient
(Kd) of the column for the elution volume (Ve) at any given peak
was calculated as:
Kd = (Ve — V0)/(V — V0).
In vitro dialysis
Peritoneal dialysate from the continuous ambulatory perito-
neal dialysis uremics (N = 4) and plasma from normals (N = 6)
and uremics (N = 6) was obtained to study the in vitro
dialyzability of chromogranin A immunoreactivity. One ml
from each sample was dialyzed overnight at 4°C in vitro against
I liter of buffer (10 mg/mi ovalbumin, 0.15 M sodium chloride,
0.01 M sodium phosphate, pH = 7.4) using standard cellulose
dialysis tubing (approximate 5,000 dalton permeability cutoff;
Spectrapor, Fisher).
Chromogranin A region-specific immunoextraction
Rabbit antisera were raised by intradermal immunization.
The antibody directed against the human chromogranin A
whole molecule recognized mid-molecule but not N- or C-
terminal epitopes [9]. Antisera were also raised against a
synthetic human/bovine synthetic N-terminal 17-mer
(LPVNSPMNKGDTEVMKY) and a synthetic bovine chro-
mogranin A C-terminal 16-mer (YELEKVAHQLEELRRG) by
coupling them to the carrier keyhole limpet hemocyanin (Cal-
biochem, San Diego, California, USA) via bisdiazobenzidine
[101 and injecting them intradermally [11]. These antisera all
recognized human chromogranin A on immunoblots, at optimal
titers (vol/vol) of 1:100 (anti-N-terminal, and anti-C-terminal) or
1:1000 (anti-whole/mid-molecule).
Anti chromogranin A antibodies were purified by ammonium
sulfate precipitation [12], and then coupled to cyanogen bro-
mide activated Sepharose (Pharmacia, Piscataway, New Jer-
sey, USA) at 10 mg protein/mi beads [12]. Two hundred
microliter plasma samples (obtained from one normal control
and one end-stage renal disease patient) were then incubated
with 10 mg (30 pi) of antibody-coupled Sepharose beads in a
final volume of 600 p.1 in binding buffer (0.15 M sodium chloride,
10 m sodium phosphate, 10 mi ethylenediamine tetraacetic
acid, 0.01% Triton X-l00, pH 7.4) at 4°C overnight with
continuous shaking, after which the beads were removed by
centrifugation. Plasma chromogranin A immunoreactivity was
determined by radioimmunoassay both pre- and post-immu-
noextraction.
Chromogranin A radioimmunoassay
Human chromogranin A was measured by a soluble phase,
double antibody radioimmunoassay, as previously described
[51.
Other assays
Parathyroid hormone in serum was measured by three meth-
ods: a radioimmunoassay specific for the intact, whole mole-
cule, or its N-terminal determinants [13] (INS-PTH; normal
range, 11 to 24 pg/mI); a radioimmunoassay that detects para-
thyroid hormone as well as its C-terminal or mid-molecule
fragments [13] (MM-PTH; normal range, 50 to 330 pg/mi); and
a two-site immunoradiometric assay that detects only the
intact, full length molecule [14] (IRMA; normal range, 10 to 65
pg/mi).
Protein concentration was determined by the Coomassie
Brilliant Blue dye binding spectrophotometric method [15].
Creatinine was measured spectrophotometrically by a Beck-
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Table 1. Chromogranin A values in subjects stratified by degree of renal insufficiency
Group N
Sex
rn/f
Age
years
SBP DBP
Hg
S.
mg/di
INSPTH MM-PTH CgA
mm pg/mi ng/ml
Normal 37 26/11 41 2 125 3 75 2 0.9 0.1(N = 20)8
12 1
(N = 17)8
130 8
(N = 17)8
50 3
Renal transplant 5 4/1 43 7 122 8 75 6 1.6 0.1 24 5 1314 430 143 20
recipients (N = 4)8 (N = 4)8
NAGD 8 6/2 49 8 141 3 84 4 1.3 0.2 18 2
(N=5)a
418 92
(N=5)8
195 74
MRRD 30 24/6 55 3 147 5 91 2 4.1 0.3 44 9
(N = 23)8
2023 418(N = 23)8
252 39
ESRD 62 39/23 50 2 143 2 82 2 13.3 0.5 66 9
(N = 59)8
7938 1388(N = 59)8
559 90
Total 142 99/43 49 1 138 2 82 1 7.9 0.6
(N = 125)8
49 5
(N = 108)8
4856 830(N = 108)8
326 44
P value <0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Abbreviations are: NAGD, nonazotemic glomerular disease (Sc. < 2 mg/dl); MRRD, mid-range renal disease (Scr = 2—7.5 mg/dl); ESRD,
end-stage renal disease (SCr > 7.5 mg/dl); SBP, systolic blood pressure; DBP, diastolic blood pressure; Se,., serum creatinine; INS-PTH, intact
N-terminal specific parathyroid hormone (nI: 11—24 pg/mI); MM-PTH, C-terminal (mid-molecule) parathyroid hormone (nI: 50—330 pg/mi); CgA,
chromogranin A (nI < 112 ng/ml); P values compare the 5 groups by one-way ANOVA test. Plus-minus values are means SEM.
8 Only N samples were obtained.
lions were calculated, and that with the highest r value is
reported.
Results
In the 37 normal controls (Table 1) who were selected to
represent a large range of ages in both sexes, chromogranin A
concentrations did not vary with either age or sex, as previously
reported [5] (P > 0.1 for both).
Table 1 displays plasma chromogranin A concentration along
with serum creatinine level in five groups of subjects divided
according to renal function. There was a stepwise increase in
plasma chromogranin A concentration with deterioration of
renal status, progressing from normal controls to end-stage
renal failure subjects, and chromogranin A correlated with
serum creatinine (r = 0.43, N = 125, P < 0.01). Since serum
creatinine is inversely proportional to glomerular filtration rate,
we also plotted chromogranin A against the inverse value of
serum creatinine (l/Sr). An even more impressive inverse
correlation linked l/Sr and chromogranin A (Fig. 1, r =
—0.82,
P < 0.01).
Figure 2 presents the gel filtration elution profile for chro-
mogranin A immunoreactivity in uremic plasma. The relatively
small effective hydrodynamic size of the immunoreactivity
suggests that the retained chromogranin A immunoreactivity in
renal failure consists of fragments of the parent chromogranin A
molecule. A similar gel filtration of normal human plasma did
not yield a detectable peak, since the total chromogranin A
immunoreactivity in normal plasma was beneath the lower limit
of assay detection after the obligate dilution of gel filtration.
To further evaluate the size of these chromogranin A frag-
ments, uremic plasma (N = 6), peritoneal dialysate from
continuous ambulatory peritoneal dialysis patients (N = 4), and
normal control plasma (N = 6) were dialyzed overnight against
a physiologic solution (10 mg/mI ovalbumin, 0.15 M sodium
chloride, 0.01 M sodium phosphate, pH = 7.4). There were no
significant differences between pre-dialysis and post-dialysis
values (Table 2), which suggested that these chromogranin A
fragments were still too large to be dialyzed, that is, larger than
6000
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Fig. 1. Plasma chromogranin A as a function of the inverse of serum
creatinine in normal controls (N = 20), nonazotemic renal transplant
recipients (N = 5), nonazotemic glomerular disease subjects (N = 8,
serum creatinine <2 mg/dl), mid-range renal disease subjects (N = 30,
serum creatinine = 2—7.5 mg/d!), and end-stage renal disease subjects
(N = 62, serum creatinine >7.5 mg/dl). Plasma chromogranin A rose
with deterioration of renal function (r =
—0.82, N = 125, P < 0.01).
man creatinine analyzer (Beckman Instruments, Palo Alto,
California, USA).
Plasma norepinephrine and epinephrine were determined by
the radioenzymatic method [16].
Statistical analysis
Results are reported as mean value the standard error of
the mean (sEM), unless otherwise stated. Descriptive statistics
(mean and standard error) and inferential statistics (one-way
analysis of variance (ANOVA), paired and unpaired t-tests,
simple regression, and multiple regression) were generated by
statistics software packages (Cricket Graph and StatWorks,
Cricket Software, Philadelphia, Pennsylvania) on a Macintosh
microcomputer. Simple, logarithmic, and exponential correla-
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Table 2. In vitro dialyzability of chromogranin A immunoreactivity (nglml)°
Subjects Fluid N
Pre-
dialysis
Post-
dialysis Paired-i P
Normals Plasma 6 41 4 37 4 1,39 0.22
Uremics Plasma 6 655 74 651 107 0.10 0.93
Uremics Peritoneal dialysate 4 27 4 21 2 2.13 0.12
Uremics: serum creatinine > 7.5 mg/dl.a Plasma from normals (N = 6) and uremics (N = 6) and peritoneal dialysate from the continuous ambulatory peritoneal dialysis-treated uremics(N = 4) was dialyzed overnight at 4°C as described in the Methods section.
Table 3. Solid phase immunoextraction of human plasma chromogranin A i mmunoreactivity with anti chromogranin A region-specific antisera
Normal control plasma CgA ESRD subject plasma CgA Buffer control CgA
ng/mlng/ml % nglm/ %
Pre-extraction 105 100
Post-extraction with antibody coupled to beads:
Anti mid-molecule 18 17 (181105)
antibody
Anti C-terminal 99 94 (99/105)
antibody
Anti N-terminal 93 89 (93/105)
antibody
Preimmune rabbit serum 108 103 (108/105)
>1920 100
900 <47 (9001>1920)
1773 <92 (1773/>1920)
>1920 100 (> 1920/> 1920)
>1920 100 (>1920/>1920)
<5
<5
<5
<5
<5
Abbreviations are: CgA, chromogranin A; ESRD, end-stage renal disease.
the approximate 5 kilodalton porosity cutoff of cellulose mem-
branes.
To evaluate the region of the molecule to which these
chromogranin A fragments correspond, plasma samples were
immunoextracted with solid-phase region-specific anti-chro-
mogranin A antibodies (Table 3). In both normal and uremic
plasma, the anti-mid-molecule antibody efficiently extracted
immunoreactivity, while the anti-N- and C-terminal antibodies
were less effective, suggesting that the bulk of the circulating
immunoreactivity consisted of mid-molecule chromogranin A
fragments recognized by the radioimmunoassay.
Table 4 documents a lack of correlation between blood
pressure and plasma chromogranin A. In untreated subjects in
both the mid-range renal disease and end-stage renal disease
groups, there was no relationship of chromogranin A to blood
pressure (P > 0.1).
Table 5 compares plasma chromogranin A and corresponding
plasma catecholamine concentrations in four groups: normal
controls, mid-range renal insufficiency, end-stage renal disease,
with plasma chromogranin A either <500 nglml or >500 nglml.
Plasma chromogranin A concentration increased as a direct
function of the rise in serum creatinine (Fig. 3), while plasma
catecholamines rose in mid-range renal disease to a level as high
as that seen in end-stage renal disease. These relationships
suggest that the rise in plasma chromogranin A is the result of
renal dysfunction alone, and is not tightly coupled to sympatho-
adrenal activation.
Figure 4 examines the relationship of parathyroid hormone
(MM-PTH and INS-PTH) to renal function and plasma chro-
mogranin A. Parathyroid hormone rose with increasing serum
creatinine (for MM-PTH: r = 0.327, N = 91, P < 0.01; for
INS-PTH: r = 0.20; N = 91, P > 0.05), and displayed an even
more significant rise with decrease of glomerular filtration rate
(1/creatinine, or l/Sr). There was a modest correlation be-
tween chromogranin A and parathyroid hormone (Fig. 4, P <
0.05).
To determine whether chromogranin A in end-stage renal
disease is more tightly linked to renal function (creatinine) or
parathyroid function (parathyroid hormone), we utilized multi-
ple linear regression, with creatinine and parathyroid hormone
(both MM-PTH and INS-PTH) as independent variables and
V0 125l-chromogranin A Vt
50
40
30
Fraction number
Fig. 2. Characterization of the size of uremic plasma chromogranin A
immunoreactivity by ge/filtration. The chromatography was performed
with a 0.9 by 55 cm Ultrogel ACA-22 column, equilibrated and eluted
with 0.15 M sodium chloride, 0.1% (wt/vol) sodium azide, 0.1% (wt/vol)
ovalbumin, and 0.01 M sodium phosphate (pH 7.4). The column was
standardized for void volume (V0) by elution of blue dextran, total
internal volume (Vi) by potassium chloride, and the elution position of
purified, '251-labeled human chromogranin A. The horizontal arrow in
the lower right-hand corner of the panel indicates the lower limit of
detection in the radioimmunoassay in which these samples were as-
sayed.
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Table 4. Influence of blood pressure upon p1asma chromogranin A in MRRD and ESRD in subjects not receiving antihypertensive drugs
Group N
Age
years
SBP DBP Scr
mg/di
INS-PTH
pg/mi
CgA
ng/mImm Hg
MRRD
Normotensive 7 50 6 137 10 82 2 3.1 0.4 36 11 (N = 6) 174 33
Hypertensiveb 8 65 2 172 9 105 4 4.5 0.7 54 18 (N = 2) 184 32
P value — <0.05 <0.01 <0.01 >0.1 >0.1 >0.1
ESRD
Normotensive 16 52 4 137 5 74 1 13.1 0.9 75 15 (N = 14) 475 51
Hypertensiveb 4 37 5 146 6 95 3 13.5 4.5 139 57 335 114
P value — >0.1 <0.01 <0.01 >0.1 >0.1 >0.1
Abbreviations are: MRRD, mid-range renal disease (Se. = 2.0—7.5 mg/dl); ESRD, end-stage renal disease (Scr > 7.5 mg/dl); SBP, systolic blood
pressure; DBP, diastolic blood pressure; Sr, serum creatjnjne; INS-PTH, intact N-terminal specific parathyroid hormone (nI: 11—24 pg/mI); CgA,
chromogranin A (ni < 112 ng/ml). Plus-minus values are means SEM.
a Only N samples were obtained.b Hypertensive = SBP> 160 mm Hg or DBP > 90 mm Hg or both.
Table 5. Chromogranin A versus catecholamines in renal failure
Group
Serum
creatinine
Plasma catecholamines Plasma
CgANE EPI
subgroup N mg/d! pg/mi pg/mi ng/mi
Normal 37 0.9 0.1 219 l2(N = 22) 44 6(N= 22) 50 3
controls
MRRD 5 3.0 0.2 1013 384 132 24 211 48
ERSD 9 16.9 1.9 832 127 75 17 475 50
with CgA
<500 ng/ml 5 13.3 2.0 830 231 55 11 351 21
>SOOng/ml 4 21.4 1.9 834 88 99 35 630 7
Abbreviations are: NE, norepinephrine; EPI, epinephrine; CgA, plasma chromogranin A; MRRD, mid-range renal disease (Se. = 2—7.5 mgldl);
ESRD, end-stage renal disease (Se,.> 7.5 mg/dl).
a Only N samples were obtained.
Table 6. Chromogranin A values in ESRD subjects: Relationship to creatinine and parathyroid hormone measurements analyzed by multiple
linear regression
Dependent
variable
Independent
variables Coefficient t statistic N F1'
(Chromogranin A) = Ala X (creatinine) ÷ B x (MM-PTH) + a constant
CgA Creatinine
MM-PTH
Constant
31
0
98
5.06
0.09
1,46
59
59
<0.01
0.93
0.15
(Chromogranin A) = A2 x (creatinine) + B2 x (INS-PTH) + a constant
CgA Creatinine
INS-PTH
Constant
30
0.27
88
5.13
0.46
1.24
59
59
<0.01
0.65
0.22
Abbreviations are: ESRD, end-stage renal disease (Sr > 7.5 mg/dl); MM-PTH, C-terminal (mid-molecule) parathyroid hormone; INS-PTH,
intact N-terminal specific parathyroid hormone; CgA, chromogranin A.
a A1, A2, B1, B2 are coefficients corresponding to creatinine, MM-PTH, and INS-PTH
b Pvalues are obtained by multiple regression test
chromogranin A as the dependent variable. The results (Table
6) indicate that chromogranin A is most tightly linked to degree
of renal insufficiency as assayed by serum creatinine (P < 0.01),
while parathyroid hormone is a comparatively ineffective pre-
dictor of chromogranin A concentration (P = 0.93 for MM-PTH
and P = 0.65 for INS-PTH).
Table 7 shows parathyroid hormone and chromogranin A
concentrations during selective venous sampling in the neck
region of a uremic secondary hyperparathyroid subject with groups according to underlying diseases which resulted in renal
elevated plasma chromogranin A. Parathyroid hormone con- failure: glomerulonephritis, diabetes mellitus, polycystic kidney
centration "steps up" at the right and left superior thyroidal
veins, while chromogranin A remains constant, further suggest-
ing that parathyroid corelease of chromogranin A/secretory
protein I [7] is not a major determinant of plasma chromogranin
A concentration in uremia.
To investigate whether the etiology of renal failure has any
bearing on chromogranin A concentration, 62 end-stage renal
disease patients (39 male and 23 female) were stratified into five
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Serum
parathyroid
hormone
Venous sampling site
INS IRMA
pg/mi pg/mi
Serum CgA
ng/ml
R. vertebral 32 271 449
R. small vertebral 31 246 555
R. low internal jugular 35 319 491
R. superior jugular 37 282 461
Proximal L. innominate 36 315 445
L. vertebral 34 261 529
Low L. vertebral 36 264 529
Inferior thyroidal 33 353 542
Accessory inferior thyroidal 97 844 462
Thymic branch 35 279 452
R. superior thyroidal 116 5984 466
Deeper R. superior thyroidal 114 3328 503
Upper L. internal jugular 35 275 616
L. superior thyroidal 374 6128 471
Lower L. jugular 37 320 468
Superior vena cava 62 402 482
I I
Abbreviations are: INS-PTH, intact N-terminal specific parathyroid
hormone (nI: 11—24 pg/mI); IRMA-PTH, parathyroid hormone (intact,
whole molecule) measured by immunoradiometric assay (nI: 10—65
pg/mi); CgA, chromogranin A (nI < 112 nglml).
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Fig. 3. The comparative values of plasma epinephrine (pg/mi), norepi-
ne?hrine (pg/mi) and chromogranin A (ng/ml) in normal controls (•
mid range renal disease (0) and end-stage renal disease (s). Bars
denote means SEM.
disease, tubulointerstitial nephritis, and hypertension. A corn-
parison by ANOVA showed no significant variation of chro-
mogranin A by intergroup comparison (Table 8, P = 0.56).
To evaluate the effects of chronic therapeutic dialysis upon
plasma chromogranin A, all 62 patients from the end-stage renal
failure group were examined. All except three were maintained
by either hemodialysis or peritoneal dialysis. Compared with
dialyzed subjects, nondialyzed subjects had lower plasma chro-
mogranin A concentration as well as lower serum creatinine
concentration (Table 9). Thus, in the 59 dialyzed subjects, more
severe uremia apparently both necessitated dialysis and re-
sulted in greater accumulation of chromogranin A.
Mode of dialysis (hemodialysis versus peritoneal dialysis) did
not influence plasma chromogranin A or serum creatinine
(Table 10, P> 0.1).
When arterial plasma chromogranin A and total protein
concentration were evaluated in samples obtained from paired
pre-dialysis and post-dialysis periods in five hemodialysis sub-
jects, there was no significant change in either chromogranin A
(from 1307 939 to 1325 972 ng/ml, P> 0.1) or total protein
(from 87 5 to 93 4 mg/ml, P > 0.1) upon hemodialysis (Fig.
5). Furthermore, chrornogranin A immunoreactivity was not
detectable in dialysate after countercurrent exposure to urernic
blood (N = 5). These results indicate that uremic plasma
chromogranin A immunoreactivity is not hemodialyzable.
Chromogranin A dialyzability was also evaluated during
chronic ambulatory peritoneal dialysis (Table 11). Chrornogra-
nm A was detectable in peritoneal dialysate, and the amount of
. . .
immunoreactivity in peritoneal dialysate was time dependent.
In three patients who underwent four- to five-hour peritoneal
dialysate dwell time, the mean chromogranin A immunoreac-
tivity in the dialysate was 54 6 ng/ml, with a plasma
concentration of 792 128 ng/ml. In one subject whose dwell
time was 72 hours, the dialysate chromogranin A immunoreac-
tivity approached that of plasma (640 vs. 660 nglml). The
plasma chromogranin A clearance through peritoneal dialysis
was 0.52 0.08 ml/min (range 0.33 to 0.73), only a small
fraction of the previously computed total body chromogranin A
clearance in normal controls (147 mllmin) [17]. Chromogranin A
specific activity (pg/mg protein) in peritoneal dialysate was
substantially higher than that in plasma (Table 12).
Table 12 shows plasma and urinary chromogranin A immu-
noreactivity in normal controls (N = 6) and subjects with
proteinuria (N = 6). No chromogranin A immunoreactivity was
detectable in normal controls' urine, but chromogranin A was
clearly present in proteinuric urine, albeit at a far lower
concentration (ng/ml) than that found in matched plasma.
Chromogranin A specific activity (tgImg protein) was higher in
C
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Table 8. Chromogranin A values in ESRD subjects stratified by etiology of renal disease
961
Group N
Age
years
SBP DBP Sr
mg/di
LNS-PTH
pg/mi
CgA
ng/mlmm Hg
GN 28 47 3 141 3 83 2 14.0 0.9 71 14 (N = 25) 670 175
DM 14 55 3 149 6 80 3 12.7 0.9 65 22 392 35
PCKD 7 60±6 132±7 77±4 13.8±1.4 75 400±33
TIN 6 36 5 140 8 83 5 13.4 2.2 67 27 824 432
HTN 7 56±8 152±9 82±6 11.3±1.1 41 379±59
Abbreviations are: GN, glomerulonephritis; DM, diabetes mellitus; PCKD, polycystic kidney disease; TIN, tubulointerstitial nephritis; HTN,
hypertension; other abbreviations defined in Table 1. Plus-minus values are mean SEM.
a Only N samples were obtained.
Table 9. Influence of chronic therapeutic dialysis upon plasma chromogranin A in ESRD
Group N
Age
years
SBP DBP
Se,.
mg/di
INS-PTH
pg/mi
CgA
ng/mimm Hg
Undialyzed
Dialyze&
P value
3
59
—
56 4
50 2
> 0.1
157 16
142 2
> 0.1
89 6
81 2
> 0.1
8.0 0.3
13.6 0.5
<0.05
78
65
33
9 (N = 56)l
> 0.1
247 12
575 94
<0.01
Abbreviations are: ESRD, end-stage renal disease (Se,. > 7.5 mg/dl); SBP, systolic blood pressure; DBP, diastolic blood pressure; Sr, serum
creatinine; INS-PTH, intact N-terminal specific parathyroid hormone (nl: 11—24 pg/mI); CgA, chromogranin A (nI < 112 ng/ml).a Either hemodialysis (N = 52) or peritoneal dialysis (N = 7)b Only N samples were obtained.
proteinuric urine than in matched plasma, reminiscent of the
peritoneal dialysate result (Table 11).
Discussion
Chromogranin A was initially identified as a protein co-stored
and co-released with catecholamines from secretory vesicles [1,
2]. Subsequently it was found in a variety of endocrine tissues
[8, 18—22], and because its plasma concentration is elevated in
patients with peptide-producing endocrine neoplasms [5], it
may be a diagnostic tool for these endocrine tumors [51. In a
prior study [5], we found that uremic subjects with secondary
hyperparathyroidism also had elevated plasma chromogranin
A. Because uremia per se may perturb peptide hormone me-
tabolism [6], and because of the known structural and immu-
nologic similarities between chromogranin A and parathyroid
secretory protein I [7, 22, 23], we investigated the effect of renal
dysfunction and uremic (secondary) hyperparathyroidism on
plasma chromogranin A.
We found that the kidney seems to play a role in chromo-
granin A disposition or catabolism. In uremic subjects, de-
creased glomerular filtration resulted in an increase in plasma
chromogranin A concentration (Table 1, Fig. 1).
Uremic plasma gel filtration (Fig. 2) suggested that chromo-
granin A immunoreactivity consisted of fragments of the parent
chromogranin A molecule. Results of region-specific, solid-
phase immunoextraction of uremic plasma (Table 3) further
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Fig. 4. Relationships between chromogranin
A, serum immunoreactive parathyroid
hormone and renal function. Parathyroid
hormone activity was measured by either the
_—
MM-PTH assay (which detects PTH as well
as its C-terminal or mid-molecule fragments
or the INS-PTH assay (which detects the
0 100 200 300 400 whole molecule or its N-terminal determinants
INS, pg/mi [131). There was a significant relationship
between MM-PTH (left panels) and serum
creatinine (r = 0.327, N = 91, P < 0.01) and
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12 = 0.064 creatinine (r = 0.489, N = 91, P < 0.01). The
N = 91 correlation between chromogranin A and MM-
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Table 10. Plasma chromogranin A values in dialyzed ESRD subjects stratified by type of dialysis
Group N
Age
years
SBP DBP S.
mg/di
INSPTH
pg/mi
CgA
ng/mimm Hg
Hemodialysis 52 52 2 144 3 82 2 13.7 0.6 64 10 (N = 50) 573 106
Peritoneal dialysis 7 35 3 127 7 78 4 12.8 0.6 75 18 (N = 6) 587 104
P value — <0.01 <0.05 > 0.1 > 0.1 > 0.1 >0.1
Abbreviations are: ESRD, end-stage renal disease (Sr> 7.5 mg/dl); SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum
creatinine; INS-PTH, intact N-terminal specific parathyroid hormone (nI: 11—24 pg/mI); CgA, chromogranin A (nl < 112 ng/ml).a OnlyN samples were obtained.
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Table 11. Effect of continuous ambulatory peritoneal dialysis on
chromogranin A in ESRD (N = 4)
Parameter
Mean
SEM Range
Chromogranin A ng/mi
Plasma 759 97 535 to 930
Dialysate 200 147 43 to 640
Chromogranin A plasma 0.52 0.08 0.33 to 0.73
clearance mi/mm
Total protein mg/mi
Plasma 87 7 62 to 99
Dialysate 7.2 7.0 0.23 to 34
Chromogranin A specific activity
ng/mg protein
Plasma 8.0 0.9 6 to 10
Dialysate 116 36 l9to 190
Conditions of continuous ambulatory peritoneal dialysis are given in
the Methods section.
support the idea of circulating chromogranin A fragments, most
of which possess mid-molecule epitopes. Bidirectional (N-
terminal and/or C-terminal) proteolytic processing of chromo-
granin A has been demonstrated in chromaffin granules [11, 24].
While we were unable to detect urinary chromogranin A
Fig. 5. Standard curve of the human
chromogranmn A radioimmunoassay, and pre-
and post-hemodiaiysis chromogranin A
immunoreactivity in a uremic subject. B/B0
for '251-chromogranin A is plotted versus log10
of added unlabeled chromogranin A or uremic
plasma. B = counts per minute (minus blank)
for any given assay tube; B0 = counts per
minute (minus blank) for maximum-binding
assay tubes, without added unlabeled standard
or unknowns. Symbols are: (O----O)
I I I I i pre-hemodialysis chromogranin A immunoreac-
1000 tivity in a uremic subject; (----L) post-hemodialysis chromogranin A immunoreactiv-
ity in the same uremic subject.
Table 12. Plasma and urinary chromogranin A in subjects with
proteinuria
Normal controls Proteinuri
N 6 6
Plasma or serum
Chromogranin A ng/mi 41 4 268 85
Creatinine mg/di 0.9 0.1 3.6 1.0
Total protein mg/mi — 68 10
Chromogranin A specific — 4.6 1.5
activity ng/mg protein
Urine
Chromogranin A ng/mi Undetectable (< 5 ng/ml) 62 16
Creatinine mg/di 113 44 80 17
Total protein mg/mi Undetectable 0.6 0.2
Chromogranin A specific Undetectable 162 48
activity ng/mg protein
immunoreactivity in normal controls, chromogranin A immu-
noreactivity was clearly present in the urine of subjects with
proteinuria (Table 12), at a higher "specific activity" (g
chromogranin A/mg protein) than the corresponding plasma
sample. Since chromogranin A, at a Stokes radius of 77 to 80 A
0
1.0 —
0.8 —
0.6 -
0.4 -
0.2 -
0
0.1
I I huh1 I I uituuil I I 1111111
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Human chromogranin A, ng/tube
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[1] is unlikely to be filtered at the glomerulus as the intact
molecule, the urinary chromogranin A immunoreactivity likely
also represents chromogranin A fragments filtered by damaged
glomeruli.
Both INS-PTH and MM-PTH rose as renal function deterio-
rated (Fig. 4), with an especially marked elevation of MM-PTH
as a function of the fall in renal function (i/Sc,.); such changes
in parathyroid hormone have previously been reported [24—26].
There was only a modest correlation (r = 0.22) between
chromogranin A and the indices of parathyroid activity (MM-
PTH and INS-PTH). Once a serum creatinine (renal function)
effect on chromogranin A and parathyroid hormone (either MM
or INS) was factored out, using multiple regression (Table 6),
there was no further correlation between parathyroid function
and chromogranin A concentration (Table 6). Furthermore,
chromogranin A and parathyroid hormone values from neck
venous catheterization illustrated a dissociation between para-
thyroid hormone and chromogranin A secretion in uremia
(Table 7). Thus, we conclude that in uremic (secondary) hyper-
parathyroidism, parathyroid cosecretion of parathyroid hor-
mone and chromogranin A/secretory protein I [7], is not a major
determinant of the chromogranin A elevation.
Subjects who are dialyzed have higher plasma chromogranin
A concentrations than those who are not dialyzed (Table 9),
simply consistent with more advanced uremia, as suggested by
higher serum creatinine. Chromogranin A is not affected by nor
filtered by hemodialysis (Fig. 5). We detected chromogranin A
immunoreactivity in peritoneal dialysate (Table 11). In both
peritoneal dialysate (Table 11) and proteinuric urine (Table 12),
chromogranin A specific activity (p.g/mg protein) is higher than
that of matched plasma. Perhaps the fragmented chromogranin
A molecule in uremic plasma is small enough to allow filtration
across both peritoneal and damaged glomerular membranes.
The peritoneal dialysate chromogranin A immunoreactivity was
not so small, however, as to be filterable across cellulose
dialysis tubing (Table 2).
Finally, we found that neither etiologic diagnosis (Table 8),
catecholamine release (Table 5, Fig. 3), nor blood pressure
(Table 4) were closely linked to chromogranin A concentration
in renal failure.
In conclusion, plasma chromogranin A rises with deteriora-
tion of renal function, and this elevation is apparently indepen-
dent of augmented sympathoadrenal activity or hyperparathy-
roidism. Rather, the rise seems to reflect a retention of
fragments of chromogranin A in uremia. Thus, when chromo-
granin A is used as a tool for evaluation of peptide or amine or
peptide hormone storage and release, and especially in the
diagnosis of neuroendocrine neoplasms, it is essential that
subjects' renal status be taken into consideration.
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